CagriSema research: studies, doses and safety

• Weeks 1-16: REDEFINE 1 used a 16-week period of gradually increasing weekly doses under trial supervision.
• Weeks 17-68: The trial then continued weekly injections through a 52-week maintenance phase.
• Week 68: REDEFINE 1 found average weight loss of 20.4% versus 3.0% with placebo, with stomach side effects common.

REDEFINE 1 studied weekly cagrilintide plus semaglutide for 68 weeks in adults without diabetes.

33 unique registered combination studies plus one simulated-use pen study. Includes ongoing/unreported records; reviews and secondary analyses are not new trials.

Key studies

• Phase 1b: six combination doses: Early combination testing supported weekly dosing and further trials. (source)
• Combined versus separate injections: Status: completed. No clinical benefit is established by registration. (source)
• Phase 2: combination versus each drug: The combination added weight loss; its HbA1c advantage over semaglutide was not significant. (source)
• MASH trial: exploratory CagriSema arm: This exploratory combination arm did not establish a liver-fibrosis benefit. (source)
• REDEFINE 2: obesity with diabetes: The combination reduced weight and HbA1c in people with type 2 diabetes. (source)
• REDEFINE 1: obesity without diabetes: The combination reduced weight more than placebo; its components also had separate arms. (source)